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ABSTRACT 
 
Background & Aims: Non-invasive surrogate endpoints of long-term outcomes of patients with primary 
biliary cirrhosis (PBC) are needed to monitor disease progression and evaluate potential treatments. We 
performed a meta-analysis of individual patient data of cohort studies to evaluate whether patient 
levels of alkaline phosphatase and bilirubin correlate with their outcomes and can be used as surrogate 
endpoints.  
 
Methods: We performed a meta-analysis of data from 4845 patients included in 15 North American and 
European long-term follow-up cohort studies. Levels of alkaline phosphatase and bilirubin were 
analyzed in different settings and sub-populations, at different time points relative to the clinical 
endpoint (liver transplantation or death).  
 
Results: Of the 4845 patients, 1118 reached a clinical endpoint. The median follow-up time was 7.3 
years; 77% survived for 10 years after study enrollment. Levels of alkaline phosphatase and bilirubin 
measured at study enrollment (baseline) and each year for 5 years were strongly associated with clinical 
outcomes (lower values associated with longer transplant-free survival). At 1 year after study 
enrollment, levels of alkaline phosphatase 2.0-fold the upper limit of normal (ULN) best predicted 
patient outcome (C statistic, 0.71), but not significantly better than other thresholds. Of patients with 
alkaline phosphatase levels ≤2.0-fold the ULN, 84% survived for 10 years, compared to 62% of those 
with levels >2.0-fold the ULN (P<.0001). Absolute levels of alkaline phosphatase 1 year after study 
enrollment predicted patient outcomes better than percentage change in level. One year after study 
enrollment, a bilirubin level 1.0-fold the ULN best predicted patient transplant-free survival (C statistic, 
0.79). Of patients with bilirubin levels ≤1.0-fold the ULN, 86% survived for 10 years after study 
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enrollment, compared with 41% of those with levels >1.0-fold the ULN (P<.0001). Combining levels of 
alkaline phosphatase and bilirubin increased the ability to predict patient survival times. We confirmed 
the predictive value of alkaline phosphatase and bilirubin levels in multiple subgroups, such as patients 
who had not received treatment with ursodeoxycholic acid, and at different time points after study 
enrollment. 
 
Conclusions: Levels of alkaline phosphatase and bilirubin can predict outcomes (liver transplantation or 
death) of patients with PBC , and might be used as surrogate endpoints in therapy trials.  
 
KEYWORDS: autoimmune liver disease; response to treatment; biomarker; new therapies. 
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INTRODUCTION 
 
Primary biliary cirrhosis (PBC) is a rare, chronic and slowly progressive autoimmune hepatobiliary 
disease. PBC typically progresses to cirrhosis, which may lead to premature death from liver failure and 
its complications.
1
 Presently the vast majority of patients are treated with ursodeoxycholic acid (UDCA), 
the only approved therapy for PBC, in keeping with treatment guidelines.
2, 3
 While UDCA therapy has a 
marked impact on clinical outcomes in PBC, up to 40% of patients have an insufficient response to UDCA 
and accordingly have a significantly increased risk of developing an adverse outcome, such as liver 
transplantation or death.
4-8
 Therefore, there remains a pressing unmet medical need for better 
therapies for this serious disease. 
A major challenge for patients, healthcare providers and drug developers, however, is the slowly 
progressive nature of the disease which effectively precludes the evaluation of classical clinical outcome, 
such as transplant-free survival. The low prevalence of PBC also represents a significant barrier to the 
conduct of large controlled clinical outcome trials in PBC. Hence while clinical endpoints such as liver 
transplantation and death have been evaluated in an early primary interventional trial in PBC with 
UDCA,9 the majority of patients are now diagnosed at an earlier stage of disease and started on UDCA 
therapy shortly after diagnosis, further impacting the ability to assess the clinical benefit of new PBC 
therapies in a timely and realistic manner. Thus, the evaluation of scientifically valid surrogate 
parameters for clinical outcomes is inevitable at least at some stage in the development pathway. 
Further evaluation of possible surrogates for clinical benefit are needed, particularly with a focus on 
using large datasets that are representative of the spectrum of disease globally, and sufficiently 
powered through size, duration of follow-up and numbers of clinical events in order to refine the 
scientific validity of specific biochemical surrogates.  
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Serum bilirubin is well established as independent predictor of prognosis in PBC, regardless of 
treatment.
10-12
 In addition, bilirubin has previously been shown to be predictive of clinical outcomes 
across other liver diseases and is incorporated in several commonly used prognostic scoring models, 
such as the Child-Turcotte-Pugh score,
13, 14
 the Model of End stage Liver Disease (MELD)
15
 and, 
specifically in PBC, the Mayo PBC score.
16
 However, despite the proven prognostic value of bilirubin, 
only those patients with relatively advanced disease are likely to demonstrate meaningful changes in 
bilirubin values that are stratifying. A biochemical variable and potentially more broadly applicable 
surrogate endpoint is alkaline phosphatase, an isoenzyme involved in dephosphorylation.
17
 Elevated 
alkaline phosphatase, a marker of cholestasis, is typically seen across the spectrum of PBC disease 
severity and is a key component of the diagnosis of PBC in both the American and European guidelines. 
2, 3
 The relationship between alkaline phosphatase values and the risk for adverse outcome in PBC has 
been extensively documented in several relatively small studies,
4, 5, 7, 8, 18, 19
 but no systematic effort has 
been reported to date using a pooled meta-analysis approach, to validate a biochemical surrogate for 
the use in PBC clinical studies.  
We sought to investigate how serum alkaline phosphatase and bilirubin values, individually and 
in combination, correlate with transplant-free survival to determine the prognostic significance of these 
biochemical variables and hence their utility as robust surrogate endpoints for therapeutic PBC trials. To 
do so, we assembled a large, international observational PBC database allowing for a robust individual 
patient-level meta-analysis, to ensure both a rigorous statistical assessment and widespread 
applicability. 
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METHODS 
 
Study design and study  population 
This study was a meta-analysis performed by the Global PBC Study Group, an international and 
multicenter collaboration between 15 liver centers in 8 North American and European countries, which 
combined individual patient data from major long-term follow-up cohorts. Most individual databases 
contained prospectively collected follow-up data on patients starting with UDCA treatment.  
This study was conducted in accordance with the protocol and the principles of the Declaration 
of Helsinki. The protocol was reviewed and approved by the Institutional Research Board of the 
corresponding center, and at each participating center, in accordance with local regulations.  
Both UDCA treated and non-treated individuals with an established diagnosis of PBC in 
accordance with European and American guidelines were eligible for inclusion.
2, 3
 Patients were 
excluded from analysis if follow-up data were insufficient or unavailable, when the start date of 
treatment or the exact date of major clinical events was unknown or if there was concomitant liver 
disease.  
 
Data collection and quality assessment 
Collected clinical and laboratory data included gender; age; PBC diagnosis; liver histology; treatment 
(type of medication, dosage and duration); duration and last date of follow-up; baseline 
antimitochondrial antibody (AMA) status; baseline and yearly laboratory values (serum alkaline 
phosphatase, total bilirubin, albumin, AST, ALT, γ-GT and platelets); outcomes (death and cause of 
death, liver transplantation, hepatocellular carcinoma, ascites and variceal bleeding).  
Liver histology performed within one year of study entry, or documented cirrhosis prior to study 
entry, were classified as a baseline biopsy. Histological data was assessed for severity according to 
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Ludwig
20
 and Scheuer’s
21
 classification. Disease stage was classified histologically as early (stage I and II) 
or late (stage III or IV) and biochemically using serum albumin and bilirubin values. According to this 
biochemical classification early stage was defined if both bilirubin and albumin were normal; moderately 
advanced disease if one of these criteria were abnormal and advanced disease if both were abnormal.
22
 
Completeness, plausibility and validity of the data was carefully verified. Extensive efforts 
including site visits with review of medical charts,  were undertaken to retrieve missing data. Data of the 
original cohorts was collected through to the end of December 2012. 
 
Statistical analysis 
The study entry was defined as start date of UDCA therapy or date of first center visit for UDCA non-
treated patients. The primary endpoint was defined as a composite of either liver transplantation or 
death. Patients without documented events during the course of the follow-up were censored at their 
last follow-up visit.  
To study the association between the absolute alkaline phosphatase and bilirubin values the 
hazard ratios (HR) of liver transplantation or death were estimated by applying a cubic  spline function 
of alkaline phosphatase and bilirubin at baseline and yearly, up to five years follow-up. 
To find an optimal threshold for each variable, alkaline phosphatase and bilirubin values at one 
year follow-up were categorized according to multiple thresholds ranging from 1.0-3.0x the upper limit 
of normal (ULN), in steps of 0.1 (and also including 1.67xULN7 for alkaline phosphatase values). The C 
statistic was calculated for each of these thresholds to evaluate their ability to predict liver transplant-
free survival. Accompanying HR were calculated for each threshold using Cox proportional hazard 
regression model. The log-likelihood test was used to assess significance. Transplant-free survival was 
assessed for the peak thresholds of alkaline phosphatase and bilirubin values and for a combination of 
both, by Kaplan-Meier estimates. Log-rank test was used for comparisons between groups.  
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In addition to the predictive ability of absolute values of alkaline phosphatase, the percentage 
change in alkaline phosphatase values
4
 from baseline to one year follow-up was evaluated using a same 
approach. 
All analyses were stratified by center to account for possible heterogeneity across center 
populations. The effects of alkaline phosphatase and bilirubin were adjusted for year of diagnosis, age at 
study entry, UDCA treatment and gender.  
To investigate if alkaline phosphatase and bilirubin are meaningful surrogate endpoints the 
association with the clinical endpoint must hold true independent of time and specific patient 
subgroups. Therefore, the survival analyses were repeated at different time points and for multiple 
subgroups of patients. The time points analysed were baseline and yearly, up to five years follow-up. 
Given the nature of this study, alkaline phosphatase or bilirubin were not always available for every 
patient at these time points. Accordingly, we aimed for the optimal use of the available data by 
assessing the association with hard clinical endpoints at baseline and several intervals thereafter, up to 
five years. Subgroups were defined by treatment (UDCA treated and non-treated patients);  baseline 
alkaline phosphatase values (>2.0xULN and >4.0xULN); baseline bilirubin values (>1xULN and >3xULN); 
PBC disease state based on both histology and biochemistry; age at time of diagnosis (<45 years and ≥45 
years)23; gender; and date of diagnosis (<1990, 1990-1999, 2000-2009). 
Normally distributed data was presented as mean ± standard deviation and skewed distributed 
data as median and interquartile range (IQR). All analyses were two-sided. A p-value <0.05 was 
considered statistically significant. Statistical analyses were performed with IBM SPSS Statistics 22.0 
(SPSS Inc, Chicago, IL, USA) and SAS 9.3.  
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RESULTS 
 
Baseline data 
Data were obtained from a total of 6191 individuals with PBC, of whom 4845 met the inclusion criteria 
(Figure 1). A total of 65,642 patient visits and a mean of 11 visits per patient were reported across the 
entire cohort, with a median of 132 elapsing days between visits. Cohort characteristics per center are 
summarized in Supplementary Table 1. The year in which patients had been diagnosed with PBC ranged 
from 1959 to 2012. The diagnosis was established after 1990 for 79% of patients, while the median year 
of diagnosis was 1998 (IQR 1991-2004). The median follow-up was 7.3 (IQR 3.6-11.5) years for the 
cohort ranging from 6 months to 34 years.  
Clinical and biochemical patient characteristics are shown in Table 1. Overall, the demographics 
were consistent with previous reports of PBC disease epidemiology. The majority, 4119 (85%) patients, 
were treated with UDCA at a median dosage of 12.3 mg/kg/day (9.4-14.6). Histological stage of disease 
was available for 76% of patients who had undergone a liver biopsy; the majority having been diagnosed 
with early disease (stage I or II).  
During follow-up 1118 patients reached a clinical endpoint; 389 underwent liver transplantation 
and 729 died, of which 358 (49%) patients from liver-related causes and 245 (34%) from other causes. 
The cause of death was unknown for 126 (17%) patients. In the total cohort, the 5-year transplant-free 
survival was 88%, 10-year survival was 77% and 15-year survival was 63%. For UDCA treated patients, 
this was 90%, 78% and 66% respectively and for non-treated patients 79%, 59% and 32% respectively 
(treated versus non-treated, P<0.0001).  
The effects of factors adjusted for in further analyses are shown in Supplementary Table 2. 
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The association between alkaline phosphatase and bilirubin values and the risk of liver 
transplantation or death 
A log-linear association was observed between alkaline phosphatase values and the risk of liver 
transplantation and death after one year and up to five years follow-up, whereby higher alkaline 
phosphatase values were associated with reduced transplant-free survival. This association was also 
found for baseline alkaline phosphatase, thus irrespective of subsequent UDCA treatment (Figure 2A, 
Supplementary Figure 1A). Abnormal bilirubin values were even more strongly associated with poor 
clinical outcome at baseline and up to five years follow-up (Figure 2B, Supplementary Figure 1B).  
 
Optimal threshold for alkaline phosphatase and bilirubin values and the risk of liver transplantation 
and death 
The study population was analysed according to a multitude of thresholds for alkaline phosphatase 
values at one year follow-up. This analysis consistently showed that patients with alkaline phosphatase 
values below any of these thresholds had significantly improved transplant-free survival than patients 
with alkaline phosphatase values above the thresholds (Table 2).  
After one year follow-up, while all thresholds were predictive of outcomes, a threshold of 
2.0xULN for alkaline phosphatase values was found to have the highest predictive ability (C statistic, 
0.71;  95% CI 0.69-0.73). Notably, this threshold was not a significantly better predictor than the other 
thresholds, such as 1.5xULN8, 1.67xULN7, 19, or 3.0xULN5 (Table 2 and Supplementary Figure 2). Similarly, 
all assessed bilirubin thresholds were predictive of outcomes. For bilirubin a threshold of 1.0xULN had 
the highest predictive ability (C statistic, 0.79 95% CI 0.77-0.80) (Table 2). 
The 5-, 10- and 15-year transplant-free survival for patients with alkaline phosphatase values 
≤2.0xULN was 94%, 84% and 73% respectively and for patients with alkaline phosphatase values 
>2.0xULN this was 81%, 62% and 50% respectively (P<0.0001), as shown in  Figure 3A. 
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The accompanying 5-, 10- and 15-year transplant-free survival for patients with normal bilirubin 
after one year follow-up was 95%, 86% and 74% respectively and for patients with abnormal bilirubin 
values  65%, 41% and 30% respectively (P<0.0001) (Figure 3B).  
The prognostic information provided by alkaline phosphatase remained important in addition to 
bilirubin; the risk of liver transplantation or death of patients with alkaline phosphatase >2.0xULN was 
significantly higher in both, those patients with normal (≤1xULN) and abnormal bilirubin (>1xULN). The 
5-, 10- and 15-year transplant-free survival in the normal bilirubin group for patients with alkaline 
phosphatase values ≤2.0xULN was 97%, 89% and 79% respectively, and for patients with alkaline 
phosphatase values >2.0xULN this was 95%, 82% and 68% respectively (P<0.0001). In the abnormal 
bilirubin group this was 74%, 51% and 39% respectively for patients with alkaline phosphatase values 
≤2.0xULN and 63%, 34% and 24% respectively for patients with alkaline phosphatase values >2.0xULN 
(P<0.0001) (Figure 3C).  
An alkaline phosphatase threshold of 2.0xULN was also predictive in addition to other bilirubin 
thresholds between 1.0xULN and 3.0xULN, but was not predictive in addition to bilirubin values >3xULN 
(HR 0.71; 95% CI 0.39-1.32; P=0.29). 
Comparable results were found for other alkaline phosphatase thresholds (e.g. 1.5xULN and 
1.67xULN in combination with normal or abnormal bilirubin (data not shown).  
 
The predictive value of percentage changes in alkaline phosphatase values at one year follow-up  
A prior study showed that patients who achieved a normal alkaline phosphatase or had >40% decrease 
in alkaline phosphatase values after UDCA treatment had a normal prognosis.
4
 In line with this study, 
the percentage change in alkaline phosphatase values from baseline to one year follow-up was 
predictive of outcome; the greater the percentage alkaline phosphatase decrease, the better the 
transplant-free survival (HR per 10% alkaline phosphatase change 0.98 [95% CI 0.96-0.99], P<0.01).  
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 A decrease of alkaline phosphatase >40% was found to be significant in predicting outcome 
(Supplementary Table 3).  The predictive value of percentage decrease of alkaline phosphatase values 
with UDCA treatment was independent of baseline alkaline phosphatase in patients with a  decrease 
between 0-40% and >40%, compared with patients without any decrease (Supplementary Figure 3).  
However, the  percentage decrease in alkaline phosphatase values did not add prognostic 
information to absolute alkaline phosphatase values after one year follow-up (HR per 10% alkaline 
phosphatase change: 1.00 [95% CI 0.99-1.02], P=0.72), apart from very high alkaline phosphatase values 
(>5.0xULN) (HR per 10% alkaline phosphatase change: 0.86 [95% CI 0.76-0.96], P<0.005). 
 
Predictive ability of alkaline phosphatase and bilirubin values across subgroups 
To assess if alkaline phosphatase can be used as a predictor independent of patient characteristics, the 
above analyses were repeated for a range of subgroups (Figure 4A). Of note, using an alkaline 
phosphatase threshold of 2.0xULN after one year of follow-up, was not only predictive for UDCA-treated 
patients, but also for non-treated patients. Similar results were seen in patients with baseline alkaline 
phosphatase values >2.0xULN and >4.0xULN; patients with histologically early and late disease; patients 
with biochemically early and moderately advanced disease; patients ≤45 years old at diagnosis and >45 
years at diagnosis; males and females; and regardless of year of diagnosis. alkaline phosphatase values 
were not predictive for patients with biochemical advanced disease, i.e. those patients with both 
abnormal bilirubin and albumin. A bilirubin threshold of 1.0xULN after one year follow-up, was also 
predictive in several subsets of patients (Figure 4B).  
Comparable results were found for alkaline phosphatase and bilirubin at other time points 
among almost all subgroups (Supplementary Table 4).  
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Translation into clinical practice 
For illustrative purposes the above findings were translated into a practical example (Figure 5) to 
demonstrate the association of a composite surrogate endpoint (bilirubin <1xULN and alkaline 
phosphatase <threshold) on 5-year liver transplantation-free survival in different settings. Three groups 
of high-risk PBC patients diagnosed after 1990 and initiated on UDCA treatment were defined at two 
different time points, at baseline (upper panels) and after one year of UDCA treatment (lower panels). 
The subgroups were defined as follows 1). all PBC patients, 2). patients meeting the inclusion criteria of 
a recent clinical trial: bilirubin <2xULN and (alkaline phosphatase >1.67xULN or bilirubin >1xULN)
24
 and 
3). patients with bilirubin <3xULN and (alkaline phosphatase >2xULN or bilirubin >1xULN). The surrogate 
endpoint was determined one year after inclusion. Figure 5 shows the proportion of patients reaching 
the surrogate endpoint (left panels) and accompanying transplant-free survival (right panels).        
If bilirubin <1xULN and alkaline phosphatase <2xULN is used as a surrogate endpoint in high-risk PBC 
population 3 (light grey) and if patients are already treated with UDCA for a year (lower panels) the 
proportion of patients reaching the surrogate endpoint after one additional year of UDCA treatment is 
18% (lower left panel) with an accompanying 5-year transplantation-free survival of 92% (lower right 
panel). The 5-year transplantation-free survival for patients not reaching the surrogate endpoint was 
75%.   
In summary, using higher alkaline phosphatase thresholds resulted in a lower proportion of 
patients not reaching the surrogate endpoint with a poorer corresponding 5-year transplant-free 
survival. The 5-year liver transplant-free survival following continued UDCA treatment is irrespective of 
the chosen alkaline phosphatase threshold and risk population.  
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DISCUSSION 
 
This study reports a robust and uniquely powered, independent evaluation of the largest PBC individual 
data meta-analysis assembled to date. We unequivocally demonstrate that both increased serum 
alkaline phosphatase and bilirubin values are strongly associated with reduced transplant-free survival in 
PBC, and that a combination of both variables improves prognostic prediction for patients. These 
associations are independent of use of UDCA and follow-up time and held for multiple subgroups. This 
data support that both, alkaline phosphatase and bilirubin, provide meaningful surrogate endpoints in 
PBC that can reasonably be used in clinical trials.  
Prior studies have demonstrated an association between normalisation, percentage decreases 
or absolute decreases of alkaline phosphatase values and improved prognosis upon treatment with 
UDCA.
4, 5, 7, 8, 18, 19
 The present study reports for the first time a near log-linear association between 
alkaline phosphatase values and  transplant-free survival, and clearly shows that the lower the alkaline 
phosphatase value, the greater the transplant-free survival time. This applied not only to alkaline 
phosphatase values during follow-up but also to baseline values, irrespective of subsequent UDCA 
treatment. The suitability of alkaline phosphatase as a surrogate endpoint for clinical benefit is further 
supported by the finding that the prognostic information provided by alkaline phosphatase values was 
confirmed across a wide range of subgroups such as non-UDCA treated patients, relatively young 
patients and patients with histologically early and late disease. This finding is of considerable clinical 
significance as alkaline phosphatase constitutes one of the three potential diagnostic criteria and is used 
routinely to assess disease activity.  
Our study additionally confirms that as baseline bilirubin values or bilirubin values over time 
increase, the likelihood of survival correspondingly decreases.
10
 The predictive ability of alkaline 
phosphatase values was demonstrated in addition to bilirubin to discriminate high and low-risk patients. 
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This is an important observation because bilirubin on its own is unsuitable as surrogate endpoint in 
clinical trials as it is typically elevated only when the disease has progressed to the stage where liver 
function becomes impaired. Most patients likely to be included in such studies will have normal values, 
precluding the possibility of observing potential beneficial treatment effects, based on bilirubin alone. 
 It has been suggested that the best way to evaluate the utility of a biomarker as a good 
surrogate endpoint, might be a meta-analysis of clinical trials of one or more interventions.
25
 A four-
level hierarchy of evidence to consider the validation of surrogate endpoints was proposed.
26
 ‘Level 1: a 
true clinical-efficacy measure; Level 2: a validated surrogate endpoint (for a specific disease setting and 
class of interventions); Level 3: a non-validated surrogate endpoint, yet one established to be 
“reasonably likely to predict clinical benefit” (for a specific disease setting and class of interventions); 
Level 4: a correlate that is a measure of biological activity but that has not been established to be a 
higher level.’  
The particular challenges in PBC to confirm biomarkers as surrogate endpoints is that there is just one 
approved treatment, and previous meta-analyses on published clinical trials, that have been conducted 
in PBC, have been interpreted in conflicting ways.
27-29
 Interpretation of the data is compromised due to 
design issues such as a lack of consistent long-term follow-up.29, 30 Our approach was therefore to 
conduct a more rigorous patient-level meta-analysis collected from existing cohorts of patients at 
centers across North America and Europe with long-term follow-up data of large numbers of PBC 
patients. This design has sufficient power to intensively study alkaline phosphatase and bilirubin as 
potential surrogate endpoints in different settings, sub-populations and at different time points. Based 
on these current results we postulate that alkaline phosphatase and bilirubin are “reasonably likely to 
predict clinical benefit” in PBC.
26
  This is of relevance to future trial design for new therapeutic agents. 
Alternative surrogates have been suggested, such as liver histology,
31
 which may provide key 
information on treatment effects in PBC. However, liver biopsy is not routinely conducted in patients 
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with PBC. Given its invasive nature and small, but well recognized risks,
32
 liver histology, with its added 
inherent sampling variability, is not an ideal  surrogate for widespread use in PBC. Non-invasive 
elastography-based assessment of liver fibrosis may potentially be used as a reliable alternative in the 
prediction of fibrosis,
33
 however further long-term evaluation is required in PBC. Similarly other 
biochemical surrogates have been suggested,
5, 6, 34
 but as of yet are not widely studied. We focused on 
the routine biochemical measurements that have been used for many years in both the diagnosis and 
management of PBC patients as this approach is likely to be the most easily applied in practice.  
There are some limitations to our study. The availability of some clinical data (such as ascites, 
edema, pruritus, fatigue or use of diuretics) and laboratory data (including PT, IgM and IgG values) in the 
individual databases varied considerably. In many cases, in particular when databases contained data of 
patients entered more than 10-20 years ago, it was not possible to collect these data consistently in a 
reliable way. Further, no uniform or generally accepted or validated methods had been used in the 
contributing centers to quantify subjective signs and symptoms. As a consequence, within the context of 
this study, we were unfortunately unable to include this type of information in our analyses and, in 
particular, were not able to calculate the Mayo Risk score
16
 and to compare the prognostic information 
provided by this established prediction tool with that provided by alkaline phosphatase and bilirubin.  
Due to the nature of our study, biochemical data was not always available at the fixed time points 
during follow-up. This was mainly encountered when the original data had been collected more than 
twenty years ago. Dose changes or interruption of UDCA treatment was also not uniformly available. 
However, we believe that these limitations had no major impact on the reliability of the results 
considering the unique large size of the study population, the prospective nature of most of the data, 
the inclusion of both UDCA treated and non-treated patients, the substantial incidence of clinical 
endpoints and the duration of follow-up. Additionally, adjusting for missing data by multiple imputation 
of the data the results did not actually change (Supplementary Table 5).    
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Based on our present results any decrease in alkaline phosphatase or bilirubin values translates 
into improved prognosis; lower values are clearly associated with better transplant-free survival. In our 
population the most discriminative alkaline phosphatase threshold after one year follow-up was 
2.0xULN, an earlier proposed threshold,
18
 although an alkaline phosphatase threshold of  1.5xULN,
8
  
1.67xULN,
7, 19
 or 3.0xULN will all work well as a surrogate endpoint in a clinical trial setting. For bilirubin 
the choice of threshold is even clearer, the spline plots (Figure 1) suggest that a choice of bilirubin 
<1.0xULN is reasonable. However, designing clinical trials implies the a priori requirement to estimate 
the quantitative effect of an experimental intervention on a given endpoint. Based on the current study 
we are not able to translate this data into a specific threshold for a clinical trial in general.  
In conclusion, our study shows that alkaline phosphatase and bilirubin values strongly correlate 
with the ultimate outcomes of death and liver transplantation in patients with PBC; the lower the 
alkaline phosphatase and bilirubin values, the better the transplant-free survival times. This robust 
analysis suggests that these variables can reasonably be regarded as useful surrogate endpoints in 
clinical trials. There is a high unmet medical need for new therapies in this rare autoimmune liver 
disease and this  study provides an important impetus for the selection of appropriate endpoints and to 
facilitate the conduct of meaningful therapeutic intervention trials, in the absence of long-term outcome 
studies. 
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FIGURE LEGENDS 
 
Figure 1. Flow chart 
Flow diagram of patients included in this study.  
 
Figure 2. Hazard of liver transplantation or death for alkaline phosphatase and bilirubin values  
The hazard of liver transplantation or death for (A) alkaline phosphatase values and (B) bilirubin values 
at different time points estimated with cublic spline function. 
 
Figure 3. Liver transplantation-free survival 
(A) Transplant-free survival of patients with alkaline phosphatase values ≤2.0xULN versus >2.0xULN at 
one year follow-up. (B) Transplant-free survival of patients with bilirubin values ≤1.0xULN versus 
>1.0xULN at one year follow-up. (C) Transplant-free survival of patients with alkaline phosphatase 
≤2.0xULN versus >2.0xULN at one year follow-up within both, patients with bilirubin values ≤1xULN and 
>1xULN.  
 
Figure 4. Subgroup analyses of alkaline phosphatase and bilirubin values 
Hazard ratio of liver transplantation or death for (A) alkaline phosphatase values >2.0xULN versus 
≤2.0xULN and (B) bilirubin values >1.0xULN versus ≤1.0xULN at one year follow-up for different 
subgroups. 
 
Figure 5. Translation into clinical practice  
The association of a surrogate endpoint, defined as alkaline phosphatase <threshold and bilirubin 
<1xULN, on the 5-year liver transplantation-free survival in different settings. Inclusion (diagnosed 
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>1990 and initiated on UDCA) was made at baseline (upper panels) and after one year on UDCA 
treatment (lower panels). Three high risk groups were defined as follows:  1) all patients (black lines), 2) 
bilirubin <2xULN and (alkaline phosphatase >1.67xULN or bilirubin >1xULN)
24
 (dark grey lines), and 3) 
bilirubin <3xULN and (alkaline phosphatase >2xULN or bilirubin >1xULN) (light grey lines). The full lines 
represent the patients who reached the surrogate endpoint and the dotted lines those who did not. The 
left panels show the proportion of patients reaching the surrogate endpoint 1 year after inclusion and 
the right panels the corresponding 5-year transplant-free survival.   
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TABLES 
 
Table 1. Baseline patient characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AMA, antimitochondrial antibody; UDCA, ursodeoxycholic acid; ULN, upper limit of 
normal. 
 Total cohort 
(n = 4845) 
Age at entry (years)
a
 54.5 (12.0) 
Female, n (%) 4348 (90%) 
AMA+, n (%) 4280 (88%) 
Year of diagnosis
b
 1998 (1991-2004) 
Year of diagnosis, time frame 1959-2012 
Histological disease stage, n (%)
c
  
Stage I  1017 (27%) 
Stage II 862 (23%) 
Stage III 483 (13%) 
Stage IV 454 (12%) 
Not available 953 (25%) 
Biochemical disease stage, n (%)
d
  
Early 2040 (42%) 
Moderately advanced  730 (15%) 
Advanced 259 (5%) 
Not available 1816 (38%) 
Baseline alkaline phosphatase values, n (%)  
>2.0xULN 1931 (52%) 
>4.0xULN 816 (22%) 
Not available 1140 (24%) 
UDCA treated patients, n (%)
e 
4119 (85%) 
  
Laboratory data at entry
b
  
Serum bilirubin (xULN) 0.67 (0.45-1.06) 
Not available 1118 (23%) 
Serum alkaline phosphatase (xULN) 2.10 (1.31-3.72) 
Not available 1140 (24%) 
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a
Data is expressed as mean and standard deviation
  
b
Data is expressed as median and interquartile range 
c
Histological disease stage according to Ludwig and Scheuer’s classification 
d
Biochemical disease stage according to Rotterdam criteria (using albumin and bilirubin)
22
 
e
640 subjects were non-treated and 86 subjects were without definitive information on UDCA use 
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Table 2. Performance of different alkaline phosphatase and bilirubin thresholds at one year follow-up for prediction liver transplantation or 
death 
 Alkaline phosphatase (n=3710) Bilirubin (n=3681) 
Thresholds C statistic  
(95% CI) 
Hazard ratio 
(95% CI) 
P-value Number of patients  
≤/> threshold 
C statistic  
(95% C() 
Hazard ratio 
(95% CI) 
P-value Number of patients  
≤/> threshold 
1.0xULN 0.68 (0.66-0.70) 2.06 (1.69-2.52) <.001 1071/2639 0.79 (0.77-0.80) 5.06 (4.34-5.89) <.001 2941/740 
1.1xULN 0.69 (0.67-0.71) 2.14 (1.79-2.57) <.001 1306/2404 0.78 (0.77-0.80) 5.22 (4.48-6.08) <.001 3019/662 
1.2xULN 0.69 (0.67-0.71) 1.97 (1.66-2.33) <.001 1515/2195 0.78 (0.76-0.80) 5.95 (5.09-6.94) <.001 3108/573 
1.3xULN 0.69 (0.67-0.71) 2.02 (1.72-2.37) <.001 1727/1983 0.78 (0.76-0.80) 6.58 (5.61-7.72) <.001 3172/509 
1.4xULN 0.70 (0.68-0.71) 2.05 (1.75-2.39) <.001 1900/1810 0.78 (0.76-0.80) 6.87 (5.84-8.09) <.001 3219/462 
1.5xULN 0.70 (0.68-0.72) 2.14 (1.84-2.50) <.001 2030/1680 0.77 (0.76-0.79) 7.68 (6.47-9.12) <.001 3271/410 
1.6xULN 0.70 (0.69-0.72) 2.23 (1.92-2.60) <.001 2158/1552 0.77 (0.75-0.79) 8.32 (6.99-9.91) <.001 3297/384 
1.67xULN 0.70 (0.69-0.72) 2.18 (1.88-2.53) <.001 2231/1479     
1.7xULN 0.70 (0.69-0.72) 2.22 (1.91-2.57) <.001 2274/1436 0.77 (0.75-0.79) 8.99 (7.53-10.74) <.001 3323/358 
1.8xULN 0.71 (0.69-0.73) 2.31 (1.99-2.68) <.001 2393/1317 0.77 (0.75-0.78) 9.04 (7.53-10.84) <.001 3346/335 
1.9xULN 0.71 (0.69-0.73) 2.37 (2.04-2.75) <.001 2466/1244 0.76 (0.75-0.78) 9.30 (7.73-11.20) <.001 3368/313 
2.0xULN 0.71 (0.69-0.73) 2.49 (2.14-2.89) <.001 2571/1139 0.76 (0.74-0.78) 10.33 (8.50-12.54) <.001 3404/277 
2.1xULN 0.71 (0.69-0.72) 2.41 (2.07-2.80) <.001 2648/1062 0.76 (0.74-0.78) 10.66 (8.76-12.97) <.001 3417/264 
2.2xULN 0.70 (0.69-0.72) 2.38 (2.05-2.77) <.001 2714/996 0.75 (0.73-0.77) 10.31 (8.43-12.62) <.001 3439/242 
2.3xULN 0.70 (0.68-0.72) 2.37 (2.04-2.76) <.001 2774/936 0.75 (0.73-0.77) 9.98 (8.13-12.24) <.001 3449/232 
2.4xULN 0.70 (0.68-0.72) 2.37 (2.04-2.77) <.001 2831/879 0.74 (0.73-0.76) 10.43 (8.46-12.86) <.001 3461/220 
2.5xULN 0.70 (0.68-0.72) 2.31 (1.98-2.70) <.001 2885/825 0.74 (0.72-0.76) 10.08 (8.14-12.50) <.001 3473/208 
2.6xULN 0.70 (0.68-0.72) 2.40 (2.05-2.81) <.001 2934/776 0.73 (0.71-0.75) 9.81 (7.89-12.21) <.001 3482/199 
2.7xULN 0.69 (0.67-0.71) 2.38 (2.04-2.79) <.001 2983/727 0.73 (0.71-0.75) 10.08 (8.07-12.59) <.001 3487/194 
2.8xULN 0.69 (0.67-0.71) 2.26 (1.92-2.65) <.001 3036/674 0.73 (0.71-0.75) 9.80 (7.85-12.24) <.001 3495/186 
2.9xULN 0.69 (0.67-0.71) 2.32 (1.97-2.73) <.001 3072/638 0.73 (0.71-0.75) 9.49 (7.57-11.91) <.001 3507/174 
3.0xULN 0.69 (0.67-0.71) 2.31 (1.96-2.73) <.001 3104/606 0.72 (0.70-0.74) 9.10 (7.23-11.45) <.001 3516/165 
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SUPPLEMENTARY MATERIAL 
 
Supplementary figures 
Supplementary Figure 1. Hazard of liver transplantation or death for alkaline phosphatase and 
bilirubin values.  
Supplementary Figure 2. Performance of thresholds for alkaline phosphatase values.  
Supplementary  Figure 3. Liver transplant-free survival for percent decrease of alkaline 
phosphatase values.   
 
Supplementary tables 
Supplementary Table 1. Center specific characteristics of the study population. 
Supplementary Table 2. Univariable and multivariable analysis showing the effects of variables 
at baseline predictive for liver transplantation and death.  
Supplementary Table 3. Hazard ratio of  percentage change of alkaline phosphatase values 
from baseline to one year follow-up.  
Supplementary Table 4. Hazard ratio of liver transplantation or death for (A) alkaline 
phosphatase values >2.0xULN versus ≤2.0xULN and (B) bilirubin values >1.0xULN versus 
≤1.0xULN at baseline and two years follow-up for different subgroups. 
Supplementary Table 5. Multivariate analysis of treated and non-treated patients following 
multiple imputation to correct for missing data values. 
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Supplementary figures 
 
Supplementary Figure 1. Hazard of liver transplantation or death for alkaline 
phosphatase and bilirubin values.  
The hazard of liver transplantation or death for (A) alkaline phosphatase values and (B) bilirubin 
values at different time points estimated with cubic spline function. 
 
Supplementary Figure 2. Performance of alkaline phosphatase thresholds.  
C statistic was performed for different thresholds for alkaline phosphatase values at one year 
follow-up. The C statistic reflects the predictive accuracy of alkaline phosphatase thresholds to 
distinguish patients with a high risk of liver transplantation or death from patients with a low risk.  
 
Supplementary Figure 3. Liver transplant-free survival for percent decrease of alkaline 
phosphatase values.   
Transplant-free survival for percent decrease of alkaline phosphatase values at one year follow-
up. (A) Transplant-free survival of patients with >40% decrease of alkaline phosphatase values,  
(B) Transplant-free survival of patients with 0-40% decrease of alkaline phosphatase values and 
(C) Transplant-free survival for patients with no decrease of alkaline phosphatase values.  
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Supplementary tables 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Supplementary Table 1. Center specific characteristics of the study population. 
Center Year of diagnosis Follow-up (in years) UDCA Alkaline 
phosphatase at 
entry 
Bilirubin at 
entry 
Country (city) N median Time frame Median (IQR) Range N % Median (IQR) Median (IQR) 
USA, 
(Rochester) 
 
857 2002  1970-2012 4.7 (2.3-9.0) 0.5-18.1 590 69% 1.63 (1.07-2.59) 0.80 (0.50-1.40) 
The Netherlands, 
(Nationwide 
cohort) 
838 1999  1961-2012 8.9 (4.8-14.2) 0.5-24.2 838 100% 2.10 (1.39-3.63) 0.61 (0.44-0.90) 
Canada, 
(Toronto) 
 
628 1999  1974-2010 7.3 (4.0-11.4) 0.5-34.3 529 84% 2.50 (1.66-4.60) 0.55 (0.40-0.82) 
Italy, (Padua) 
 
544 1989  1959-2005 7.1 (3.6-12.0) 0.5-25.8 386 71% 2.56 (1.50-4.29) 0.80 (0.54-1.38) 
UK, 
(Birmingham) 
 
363 2003  1972-2011 6.0 (3.3-9.4) 0.6-16.7 285 79% 1.91 (1.16-3.20) 0.52 (0.38-1.10) 
French, (Paris) 
 
348 1988  1974-2001 5.9 (2.1-8.9) 0.5-22.5 348 100% 3.00 (1.90-5.30) 0.67 (0.43-1.17) 
USA, (Dallas) 
 
326 1993  1977-2011 8.8 (6.9-11.6) 0.8-23.7 326 100% 2.67 (1.54-3.86) 0.46 (0.31-0.67) 
Italy, (Milan, 2 
centers) 
 
289 1999  1972-2012 7.2 (3.4-13.3) 0.5-23.8 289 96% 1.74 (1.05-3.26) 0.67(0.48-1.00) 
Spain, 
(Barcelona) 
 
273 1995  1971-2005 12.1 (7.7-16.3) 0.6-23.8 266 97% 1.89 (1.24-3.32) 0.67 (0.50-1.00) 
Belgium, 
(Leuven) 
 
150 2000  1974-2011 6.8 (3.4-12.8) 0.6-28.8 136 91% 2.75 (1.66-4.58) 0.72 (0.47-1.18) 
UK, (London) 
 
138 1994  1972-2007 8.5 (5.1-12.1) 0.5-22.5 56 41% 1.83 (1.14-3.09) 0.53 (0.41-0.71) 
Canada, 
(Edmonton) 
 
57 2003 1989-2008 5.9 (4.0-8.3) 0.7-18.4 53 93% 3.13 (2.10-5.57) 0.82 (0.57-1.24) 
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Supplementary Table 2 (continued). Center specific characteristics of the study population. 
 
 
  
  
USA, (Seattle) 
 
34 2008  1995-2012 6.0 (3.3-9.4) 0.5-16.7 30 88% 1.69 (1.11-2.68) 0.42 (0.33-0.50) 
Total 4845 1998 1959-2012 7.3 (3.6-11.5) 0.5-34.3 4119 85% 2.10 (1.31-3.72) 0.67 (0.45-1.06) 
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Supplementary Table 2. Univariable and multivariable analysis showing the effects of variables at baseline predictive for liver 
transplantation and death.  
 Univariable analysis Multivariable analysis 
 Hazard ratio (95% CI) P-value  Hazard ratio (95% CI) P-value  
Year of diagnosis (year) 0.95 (0.94-0.95) <0.001 0.95 (0.94-0.96) <0.001 
Age at study entry (year) 1.04 (1.03-1.04) <0.001 1.03 (1.03-1.04) <0.001 
UDCA treatment  0.59 (0.50-0.71) <0.001 0.61 (0.51-0.74) <0.001 
Male gender 1.52 (1.28-1.80) <0.001 1.46 (1.22-1.75) <0.001 
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Supplementary Table 3. Hazard ratio for predicting liver transplantation or death for percentage change of alkaline phosphatase 
values from baseline to one year follow-up.  
Percentage reduction of 
alkaline phosphatase 
Hazard Ratio 
(95% CI) 
P-value 
No reduction 1  
0-10%  0.88 (0.63-1.23) .45 
10-20% 0.85 (0.60-1.20) .36 
20-30% 0.67 (0.48-0.95) .03 
30-40% 0.84 (0.61-1.15) .23 
40-50% 0.70 (0.51-0.96) .03 
50-60% 0.59 (0.42-0.83) .003 
>60% 0.62 (0.44-0.86) .005 
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Supplementary Table 4. Hazard ratio of liver transplantation or death for (A) alkaline phosphatase values >2.0xULN versus 
≤2.0xULN and (B) bilirubin values >1.0xULN versus ≤1.0xULN at baseline and two years follow-up for different subgroups. 
 
Alkaline phosphatase >2.0xULN 
versus ≤2.0xULN 
At baseline 
Alkaline phosphatase >2.0xULN 
versus ≤2.0xULN 
At 2 years follow-up 
 
n= P-value HR (95% CI) n= P-value HR (95% CI) 
Year of diagnosis 2000-2009 1479 <.0001 2.23 (1.65-3.02) 1170 <.0001 2.50 (1.61-3.88) 
Year of diagnosis 1990-1999 1298 <.0001 2.05 (1.62-2.60) 1176 <.0001 2.41 (1.87-3.11) 
Year of diagnosis <1990 754 .002 1.54 (1.17-2.04) 579 <.0001 2.41 (1.78-3.25) 
Female 3320 <.0001 1.94 (1.65-2.29) 2717 <.0001 2.75 (2.27-3.32) 
Male 385 .01 1.64 (1.11-2.42) 301 .64 1.13 (0.67-1.91) 
Age at diagnosis >45 years 2847 <.0001 1.84 (1.56-2.17) 2264 <.0001 2.35 (1.93-2.87) 
Age at diagnosis ≤45 years 858 <.0001 2.52 (1.65-3.84) 754 <.0001 3.11 (2.08-4.64) 
Advanced stage 239 .44 1.17 (0.78-1.75) 152 .57 1.17 (0.68-2.01) 
Moderately advanced stage 667 .79 1.04 (0.79-1.37) 453 .01 1.56 (1.11-2.19) 
Early stage  1905 .002 1.52 (1.16-2.00) 1347 <.0001 2.02 (1.42-2.87) 
Histological stage 3 or 4 449 .54 0.88 (0.59-1.32) 396 .0008 2.26 (1.40-3.64) 
Histological stage 1 or 2 1013 <.0001 2.63 (1.73-3.99) 866 <.0001 4.15 (2.50-6.87) 
Baseline alkaline phosphatase values >4.0xULN    557 <.0001 2.87 (1.80-4.58) 
Baseline alkaline phosphatase values >2.0xULN    1342 <.0001 2.22 (1.74-2.83) 
UDCA treated 3090 <.0001 2.01 (1.68-2.39) 2719 <.0001 2.68 (2.22-3.23) 
UDCA non-treated 537 .003 1.68 (1.19-2.37) 265 .06 1.67 (0.97-2.86) 
Entire cohort 3705 <.0001 1.87 (1.61-2.18) 3018 <.0001 2.49 (2.09-2.96) 
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Supplementary Table 4 (continued). Hazard ratio of liver transplantation or death for (A) alkaline phosphatase values >2.0xULN 
versus ≤2.0xULN and (B) bilirubin values >1.0xULN versus ≤1.0xULN at baseline and two years follow-up for different subgroups. 
 
Bilirubin >1.0xULN versus ≤1.0xULN 
At baseline 
Bilirubin >1.0xULN versus ≤1.0xULN 
At 2 years follow-up 
 
n= P-value HR (95% CI) n= P-value HR (95% CI) 
Year of diagnosis 2000-2009 1409 <.0001 4.73 (3.45-6.48) 1054 <.0001 6.55 (4.09-10.48) 
Year of diagnosis 1990-1999 1312 <.0001 5.50 (4.36-6.93) 1194 <.0001 4.54 (3.46-5.96) 
Year of diagnosis <1990 846 <.0001 4.00 (3.16-5.05) 665 <.0001 4.33 (3.22-5.82) 
Female 3332 <.0001 4.94 (4.24-5.75) 2699 <.0001 4.92 (4.06-5.97) 
Male 395 <.0001 3.50 (2.36-5.19) 295 <.0001 4.34 (2.55-7.38) 
Age at diagnosis >45 years 901 <.0001 4.27 (3.64-5.01) 2225 <.0001 4.23 (3.44-5.21) 
Age at diagnosis ≤45 years 2826 <.0001 7.25 (5.12-10.26) 769 <.0001 8.62 (5.79-12.83) 
Advanced stage    161 .01 2.33 (1.20-4.51) 
Moderately advanced stage    477 <.0001 2.49 (1.74-3.57) 
Early stage    1379 <.0001 3.70 (2.42-5.67) 
Histological stage 3 or 4 429 <.0001 3.80 (2.54-5.70) 370 <.0001 4.20 (2.73-6.48) 
Histological stage 1 or 2 946 <.0001 8.98 (5.63-14.32) 814 <.0001 5.19 (3.08-8.74) 
Baseline bilirubin values >3.0xULN    116 .35 1.51 (0.64-3.53) 
Baseline bilirubin values >1.0xULN    630 <.0001 2.09 (1.54-2.84) 
UDCA treated 3069 <.0001 5.28 (4.50-6.20) 2662 <.0001 5.05 (4.17-6.13) 
UDCA non-treated 596 <.0001 3.41 (2.42-4.81) 301 <.0001 3.53 (1.96-6.35) 
Entire cohort 3727 <.0001 4.74 (4.12-5.46) 2994 <.0001 4.87 (4.07-5.83) 
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Supplementary Table 5. Multivariate analysis of treated and non-treated patients following multiple imputation to correct for missing 
data values. 
 
 
Alkaline phosphatase >2.0xULN Bilirubin >1.0xULN 
Cohorts Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value 
Entire cohort 2.46 2.16-2.80 <.0001 4.80 4.13-5.57 <.0001 
UDCA treated patients 2.49 2.15-2.88 <.0001 4.95 4.21-5.83 <.0001 
UDCA untreated patients 2.07 1.45-2.95 <.0001 3.79 2.58-5.59 <.0001 
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